Cyllene Therapeutics
Business Services · 11-50 Employees
View Company Info for Free
Overview
Website
www.cyllene-tx.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cyllene Therapeutics
Cyllene Therapeutics is a biotechnology company developing next-generation DNA medicines and precision gene therapies for chronic diseases. The company uses a proprietary non-replicative HSV-1 vector platform to deliver targeted genetic therapies, with a focus on neurological and peripheral nervous system disorders. Its activities include biotechnology research, clinical development, and therapeutic innovation.Explore more
Cyllene Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cyllene Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cyllene Therapeutics had a recent Job posting/layoffs
Check if Cyllene Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Cyllene Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Cyllene Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cyllene Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Cyllene Therapeutics
Check out if Cyllene Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Cyllene Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Cyllene Therapeutics
Find 2 more new buyers
Cyllene Therapeutics financials insights
Gather financial insights about Cyllene Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series C
$37.7M
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Funding
Funding
Cyllene Therapeutics News & Media
Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)
Paris, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, September 14, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-systemic, site-specific therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead candidate, EG110A, a first-in-class treatment being developed to address neurogenic detrusor overactivity (NDO) with urinary incontinCyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, today announced the appointment of Alyssa Levin to its Board of Directors, where she will also serve as Chair of the Audit Committee. The company has also strengthened its leadership team with two key additions. Clara Cambon-Thiebaud
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cyllene Therapeutics
Sign Up For FreeTo access detailed company insights
Cyllene Therapeutics is a biotechnology company developing next-generation DNA medicines and precision gene therapies for chronic diseases. The company uses a proprietary non-replicative HSV-1 vector platform to deliver targeted genetic therapies, with a focus on neurological and peripheral nervous system disorders. Its activities include biotechno... Read More
